ESROGLIM M1 FORTE Tablets combine Metformin Hydrochloride 1000 mg (prolonged-release) and Glimepiride 1 mg in a convenient bilayered tablet, providing reliable and long-lasting type 2 diabetes management. This dual-action formulation works to maintain stable blood glucose levels throughout the day while improving overall glycemic control.
Form: Bilayered tablets
Composition: Metformin Hydrochloride IP 1000 mg (prolonged-release) + Glimepiride IP 1 mg
Pack Size: 10 × 15 Tablets
MRP: ₹150/-
Metformin, a first-line anti-diabetic agent, reduces glucose production in the liver and enhances insulin sensitivity, while Glimepiride stimulates the pancreas to release more insulin. Together, they target both insulin resistance and low insulin secretion—key issues in type 2 diabetes.
✔ Dual-action therapy for optimal blood sugar control
✔ Prolonged-release Metformin for all-day glucose stability
✔ Low-dose Glimepiride for gentle yet effective insulin stimulation
✔ Once-daily dosing for convenience and better compliance
✔ Reduces risk of sugar fluctuations for improved patient outcomes
Compared to single-agent therapy, this combination provides more comprehensive diabetes control in one tablet, reducing pill burden and improving treatment adherence. Ideal for patients requiring a lower Glimepiride dose to minimize hypoglycemia risk.
